Literature DB >> 19913488

Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens.

Valicia Burke1, Constance Williams, Madhav Sukumaran, Seung-Sup Kim, Huiguang Li, Xiao-Hong Wang, Miroslaw K Gorny, Susan Zolla-Pazner, Xiang-Peng Kong.   

Abstract

Human monoclonal antibodies 447-52D and 537-10D, both coded by the VH3 gene and specific for the third variable region (V3) of the HIV-1 gp120, were found to share antigen-binding structural elements including an elongated CDR H3 forming main-chain interactions with the N terminus of the V3 crown. However, water-mediated hydrogen bonds and a unique cation-pi sandwich stacking allow 447-52D to be broadly reactive with V3 containing both the GPGR and GPGQ crown motifs, while the deeper binding pocket and a buried Glu in the binding site of 537-10D limit its reactivity to only V3 containing the GPGR motif. Our results suggest that the design of immunogens for anti-V3 antibodies should avoid the Arg at the V3 crown, as GPGR-containing epitopes appear to select for B cells making antibodies of narrower specificity than V3 that carry Gln at this position.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19913488      PMCID: PMC3683248          DOI: 10.1016/j.str.2009.09.012

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  54 in total

1.  Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity.

Authors:  Michal Sharon; Naama Kessler; Rina Levy; Susan Zolla-Pazner; Matthias Görlach; Jacob Anglister
Journal:  Structure       Date:  2003-02       Impact factor: 5.006

2.  HIV vaccine design and the neutralizing antibody problem.

Authors:  Dennis R Burton; Ronald C Desrosiers; Robert W Doms; Wayne C Koff; Peter D Kwong; John P Moore; Gary J Nabel; Joseph Sodroski; Ian A Wilson; Richard T Wyatt
Journal:  Nat Immunol       Date:  2004-03       Impact factor: 25.606

3.  Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D.

Authors:  Robyn L Stanfield; Miroslaw K Gorny; Constance Williams; Susan Zolla-Pazner; Ian A Wilson
Journal:  Structure       Date:  2004-02       Impact factor: 5.006

4.  The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Authors:  Miroslaw K Gorny; Kathy Revesz; Constance Williams; Barbara Volsky; Mark K Louder; Christopher A Anyangwe; Chavdar Krachmarov; Samuel C Kayman; Abraham Pinter; Arthur Nadas; Phillipe N Nyambi; John R Mascola; Susan Zolla-Pazner
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

5.  V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.

Authors:  C P Krachmarov; S C Kayman; W J Honnen; O Trochev; A Pinter
Journal:  AIDS Res Hum Retroviruses       Date:  2001-12-10       Impact factor: 2.205

6.  Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks.

Authors:  W Resch; N Hoffman; R Swanstrom
Journal:  Virology       Date:  2001-09-15       Impact factor: 3.616

7.  Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody.

Authors:  M K Gorny; A J Conley; S Karwowska; A Buchbinder; J Y Xu; E A Emini; S Koenig; S Zolla-Pazner
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

8.  Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition.

Authors:  Frederic A Fellouse; Christian Wiesmann; Sachdev S Sidhu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

9.  Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

Authors:  Miroslaw K Gorny; Constance Williams; Barbara Volsky; Kathy Revesz; Sandra Cohen; Victoria R Polonis; William J Honnen; Samuel C Kayman; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

Review 10.  Identifying epitopes of HIV-1 that induce protective antibodies.

Authors:  Susan Zolla-Pazner
Journal:  Nat Rev Immunol       Date:  2004-03       Impact factor: 53.106

View more
  48 in total

1.  Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals.

Authors:  Miroslaw K Gorny; Ruimin Pan; Constance Williams; Xiao-Hong Wang; Barbara Volsky; Timothy O'Neal; Brett Spurrier; Jared M Sampson; Liuzhe Li; Michael S Seaman; Xiang-Peng Kong; Susan Zolla-Pazner
Journal:  Virology       Date:  2012-03-07       Impact factor: 3.616

2.  Conserved structural elements in the V3 crown of HIV-1 gp120.

Authors:  Xunqing Jiang; Valicia Burke; Maxim Totrov; Constance Williams; Timothy Cardozo; Miroslaw K Gorny; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  Nat Struct Mol Biol       Date:  2010-07-11       Impact factor: 15.369

3.  Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1.

Authors:  Anita Changela; Xueling Wu; Yongping Yang; Baoshan Zhang; Jiang Zhu; Glenn A Nardone; Sijy O'Dell; Marie Pancera; Miroslaw K Gorny; Sanjay Phogat; James E Robinson; Leonidas Stamatatos; Susan Zolla-Pazner; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

4.  Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

Authors:  Michael Vaine; Shixia Wang; Anthony Hackett; James Arthos; Shan Lu
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

5.  Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.

Authors:  Ann J Hessell; Sean McBurney; Shilpi Pandey; William Sutton; Lily Liu; Liuzhe Li; Maxim Totrov; Susan Zolla-Pazner; Nancy L Haigwood; Miroslaw K Gorny
Journal:  Vaccine       Date:  2016-04-19       Impact factor: 3.641

6.  Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes.

Authors:  Catarina E Hioe; Terri Wrin; Michael S Seaman; Xuesong Yu; Blake Wood; Steve Self; Constance Williams; Miroslaw K Gorny; Susan Zolla-Pazner
Journal:  PLoS One       Date:  2010-04-21       Impact factor: 3.240

7.  Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247.

Authors:  Karen A Kirby; Yee Tsuey Ong; Atsuko Hachiya; Thomas G Laughlin; Leslie A Chiang; Yun Pan; Jennifer L Moran; Bruno Marchand; Kamalendra Singh; Fabio Gallazzi; Thomas P Quinn; Kazuhisa Yoshimura; Toshio Murakami; Shuzo Matsushita; Stefan G Sarafianos
Journal:  FASEB J       Date:  2014-10-28       Impact factor: 5.191

8.  Computational-guided determination of the functional role of 447-52D long CDRH3.

Authors:  Edwin Kamau; Richard Bonneau; Xiang-Peng Kong
Journal:  Protein Eng Des Sel       Date:  2018-12-01       Impact factor: 1.650

9.  Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors.

Authors:  Axel Mann; Nikolas Friedrich; Anders Krarup; Jacqueline Weber; Emanuel Stiegeler; Birgit Dreier; Pavel Pugach; Melissa Robbiani; Tina Riedel; Kerstin Moehle; John A Robinson; Peter Rusert; Andreas Plückthun; Alexandra Trkola
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

10.  Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.

Authors:  Preetha Balasubramanian; Rajnish Kumar; Constance Williams; Vincenza Itri; Shixia Wang; Shan Lu; Ann J Hessell; Nancy L Haigwood; Faruk Sinangil; Keith W Higgins; Lily Liu; Liuzhe Li; Phillipe Nyambi; Miroslaw K Gorny; Maxim Totrov; Arthur Nadas; Xiang-Peng Kong; Susan Zolla-Pazner; Catarina E Hioe
Journal:  Vaccine       Date:  2017-02-06       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.